Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Paxmedica Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio is assigned to 1 distinct examiner and 1 distinct art unit, which suggests a narrow technical focus for the company's current patent applications. This concentration simplifies the prosecution process, as the company only has to manage 1 set of deadlines and 1 examiner's specific requirements. This can lead to an efficient path to allowance if the examiner's concerns are addressed effectively.
The busiest examiner, ABDALHAMEED, MANAHIL MIRGHANI ALI, is handling the 1 busiest examiner pending office action. This examiner is the point of contact for the company's 1 pending office action, making their individual examination style the most significant factor in the prosecution. With 1 distinct examiner and 1 distinct art unit, the company does not have to worry about conflicting feedback from different parts of the patent office. The focus should remain on resolving the 1 pending office action through clear communication with this specific examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033194 | ADMINISTRATION OF ANTIPURINERGIC COMPOSITIONS FOR TREATING NERVOUS SYSTEM DISORDERS | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033194 | ADMINISTRATION OF ANTIPURINERGIC COMPOSITIONS FOR TREATING NERVOUS SYSTEM DISORDERS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102§103§112DPOther | Non-Final OA | — | Pending | Apr 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial